Get the Stockscreener App
0.7732
42.16%
0.2293
After Hours:
.77
-0.0032
-0.41%
Kezar Life Sciences Inc stock is traded at $0.7732, with a volume of 16.15M.
It is up +42.16% in the last 24 hours and up +28.74% over the past month.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
See More
Previous Close:
$0.5439
Open:
$0.6147
24h Volume:
16.15M
Relative Volume:
21.81
Market Cap:
$54.72M
Revenue:
-
Net Income/Loss:
$-101.87M
P/E Ratio:
-0.6723
EPS:
-1.15
Net Cash Flow:
$-83.46M
1W Performance:
+36.46%
1M Performance:
+28.74%
6M Performance:
-14.24%
1Y Performance:
-35.03%
1-Day Range:
$0.61
$0.8262
1-Week Range:
$0.5202
$0.8262
52-Week Range:
$0.5202
$1.19
Kezar Life Sciences Inc Stock (KZR) Company Profile
Name
Kezar Life Sciences Inc
Sector
Industry
Phone
650-822-5600
Address
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Wells Fargo | Outperform |
| Jul-16-18 | Initiated | William Blair | Outperform |
Kezar Life Sciences Inc Stock (KZR) Latest News
Kezar Life Sciences Halts Trial of Lupus-Nephritis Treatment After Deaths - MarketWatch
Kezar Life Sciences pauses trial for lupus treatment after patient deaths - Reuters
Kezar halts lupus drug trial after patient deaths - Investing.com
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients - StockTitan
Kezar Life Sciences pauses trial for lupus treatment after patient deaths - AOL
Quarterly Snapshot: Quick and Current Ratios for Kezar Life Sciences Inc (KZR) - The Dwinnex
Check out these key findings about Kezar Life Sciences Inc (KZR) - SETE News
KZR’s Stock Journey: What Investors Need to Know About Kezar Life Sciences Inc’s Performance - The InvestChronicle
Selling Buzz: Kezar Life Sciences Inc [KZR] Chief Legal Officer Schiller Mark C. sells 6,688 shares of the company - Knox Daily
Kezar Life Sciences stock hits 52-week low at $0.53 By Investing.com - Investing.com Australia
A look at KZR’s current quarter earnings estimates - US Post News
Kezar Life Sciences stock hits 52-week low at $0.53 - Investing.com
Kezar Life Sciences stock hits 52-week low at $0.53 By Investing.com - Investing.com UK
JonesTrading Downgrades Kezar Life Sciences (KZR) - MSN
Acadian Asset Management LLC Raises Stake in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Perhaps timely catching Kezar Life Sciences Inc (KZR) would be a good idea - SETE News
Kezar Life Sciences Inc’s Shares Reel: -3.60% Quarterly Revenue Decline Amid 49.58M Market Cap - The InvestChronicle
Kezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Decrease in Short Interest - Defense World
Kezar Life Sciences, Inc. (NASDAQ:KZR) Shares Bought by Vanguard Group Inc. - Defense World
Kezar Life Sciences (STU:2KZ) Enterprise Value : €-92.80 Mil (As of Aug. 17, 2024) - GuruFocus.com
Brokers Offer Predictions for Kezar Life Sciences, Inc.’s FY2024 Earnings (NASDAQ:KZR) - Defense World
Kezar Life Sciences, Inc. (NASDAQ:KZR) to Post Q3 2024 Earnings of ($0.30) Per Share, William Blair Forecasts - Defense World
What is the investor’s view on Kezar Life Sciences Inc (KZR)? - US Post News
HC Wainwright Reiterates Buy Rating for Kezar Life Sciences (NASDAQ:KZR) - Defense World
KZR’s 52-Week Rollercoaster: From $0.54 to $1.68 – What’s Next for Investors? - The InvestChronicle
Kezar Life Sciences Maintains Buy Rating, Focus Shifts to Zeto Trials - Investing.com Canada
Kezar Life Sciences Maintains Buy Rating, Focus Shifts to Zeto Trials - Investing.com UK
Kezar Life Sciences Discontinues Unpromising Phase 1 Solid Tumor Drug - Benzinga
Kezar stalls solid tumour trial to focus on autoimmune disease candidate - Yahoo Finance
Kezar stalls solid tumour trial to focus on autoimmune disease candidate - Clinical Trials Arena
Kezar stalls solid tumour trial to focus on autoimmune disease candidate - Pharmaceutical Technology
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024 - InvestorPlace
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Manchestertimes
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Business Wire
Head to Head Survey: Neurogene (NASDAQ:NGNE) & Kezar Life Sciences (NASDAQ:KZR) - Defense World
Polymyositis Drugs Market Size 2032 | Argenx, Immunoforge Co. - openPR
Jacobs Levy Equity Management Inc. Cuts Stock Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Kezar Life Sciences' chief legal officer sells shares worth $3,879 - Investing.com
How did Kezar Life Sciences Inc (KZR) fare last session? - US Post News
Kezar Life Sciences, Inc. (NASDAQ:KZR) Shares Purchased by BNP Paribas Financial Markets - Defense World
Polymyositis Market to Show Remarkable Growth Trends from 2023 - openPR
Acadian Asset Management LLC Increases Stock Position in Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World
Kezar Life Sciences (NASDAQ:KZR) Given New $7.00 Price Target at HC Wainwright - Defense World
Kezar Life Sciences Inc (KZR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
You might want to take a look at Kezar Life Sciences Inc (KZR) now - SETE News
Kezar Life Sciences (NASDAQ:KZR) Trading 2.4% Higher - Defense World
Kezar Life Sciences Inc (KZR) presents a great opportunity, but the stock is slightly undervalued - US Post News
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Metric Deep Dive: Understanding Kezar Life Sciences Inc (KZR) Through its Ratios – DWinneX - The Dwinnex
Kezar Life Sciences Inc Stock (KZR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):